Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Income from Continuing Operations: 2015-2024

Historic Income from Continuing Operations for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to -$486.5 million.

  • Intellia Therapeutics' Income from Continuing Operations rose 21.02% to -$104.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$445.4 million, marking a year-over-year increase of 8.75%. This contributed to the annual value of -$486.5 million for FY2024, which is 4.51% down from last year.
  • Intellia Therapeutics' Income from Continuing Operations amounted to -$486.5 million in FY2024, which was down 4.51% from -$465.5 million recorded in FY2023.
  • In the past 5 years, Intellia Therapeutics' Income from Continuing Operations registered a high of -$134.2 million during FY2020, and its lowest value of -$486.5 million during FY2024.
  • For the 3-year period, Intellia Therapeutics' Income from Continuing Operations averaged around -$467.2 million, with its median value being -$465.5 million (2023).
  • Data for Intellia Therapeutics' Income from Continuing Operations shows a maximum YoY slumped of 98.59% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Intellia Therapeutics' Income from Continuing Operations stood at -$134.2 million in 2020, then tumbled by 98.59% to -$266.6 million in 2021, then tumbled by 68.67% to -$449.6 million in 2022, then decreased by 3.52% to -$465.5 million in 2023, then decreased by 4.51% to -$486.5 million in 2024.